Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Spotlight

Thumbnail
March 23, 2021

The Huntington’s pipeline takes a blow

The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.

Thumbnail
February 23, 2021

A three way battle beckons in GM1 gangliosidosis

Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.

Article image
Vantage logo
February 17, 2021

The big Covid-19 trials still to report

New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?

Article image
Vantage logo
January 05, 2021

Hope versus experience in glioblastoma

Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.

Article image
Vantage logo
December 04, 2020

Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline

Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.

Article image
Vantage logo
December 02, 2020

Ovid crashes out in Angelman syndrome

The failure of OV101 puts the spotlight on Ultragenyx and Roche.

Article image
Vantage logo
December 01, 2020

The promise and the perils of antigen testing

A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.

Article image
Vantage logo
November 26, 2020

Glaxo moves up a place in the RSV treatment race

The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.

Article image
Vantage logo
November 12, 2020

Interest in Tyk2 might soon tick up

Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.

Article image
Vantage logo
November 09, 2020

Aducanumab: this time it’s personal

The focus shifts to whether the FDA will overrule its own panel and approve the Alzheimer’s project.

Article image
Vantage logo
November 05, 2020

Anti-amyloid approaches come back from the dead

Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.